Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner

Liat Izhak, Gizi Wildbaum, Weinberg Uri, Yuval Shaked, Jennifer Alami, Daniel Dumont, Daniel Dumont, Avi Stein and Nathan Karin

*J Immunol* 2010; 184:5414; doi: 10.4049/jimmunol.1090025

http://www.jimmunol.org/content/184/9/5414
Corrections


The seventh author’s name was omitted from the article. In addition, the third author’s name was published incorrectly. The corrected author and affiliation lines are shown below.

Liat Izhak,* Gizi Wildbaum,* Uri Weinberg,* Yuval Shaked,† Jennifer Alami,‡ Daniel Dumont,‡ Boris Friedman,§ Avi Stein,§ and Nathan Karin*

*Department of Immunology and †Department of Pharmacology, the Ruth and Bruce Rappaport Faculty of Medicine, Rappaport Family Institute for Research in the Medical Sciences, Technion-Institute of Technology; ‡Department of Urology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel; and §Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

www.jimmunol.org/cgi/doi/10.4049/jimmunol.1090025